BONJESTA cpr ret 20mg/20mg 20 pce

7680688670028 CH-68867 R06AA59 01.09.0.
BONJESTA cpr ret 20mg/20mg 20 pce
BONJESTA cpr ret 20mg/20mg 20 pce
BONJESTA cpr ret 20mg/20mg 20 pce
1 / 3
google

Details

Product number
6886701
CPT
-
Packaging group
20
Unit
Tablette(n)
Composition
doxylamini hydrogenosuccinas 20 mg, pyridoxini hydrochloridum 20 mg, cellulosum microcristallinum, magnesii trisilicas, carmellosum natricum conexum, magnesii stearas, silica colloidalis anhydrica, Überzug: hypromellosum, triethylis citras, simeticoni emulsio cum dimeticonum et polysorbatum 65 et silica colloidalis et methylcellulosum et poly(dimethylsiloxani) elastomerum et mono/diglycerida et acidum sulfuricum et E 200 et E 210 0.007 µg, acidi methacrylici et ethylis acrylatis polymerisatum 1:1, talcum, silica colloidalis anhydrica, natrii hydrogenocarbonas, natrii laurilsulfas, poly(alcohol vinylicus), titanii dioxidum, macrogolum 3350, E 172 (rubrum), E 172 (nigrum), cera carnauba, Drucktinte: lacca, E 129, propylenglycolum, E 132, ammoniae solutio 28 per centum, simeticonum, pro compresso obducto corresp. natrium 0.38 mg.

Articles (1)

Bonjesta 20 mg / 20 mg, Tablette mit veränderter Wirkstofffreisetzung
Tablette
20
View

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Patient information leaflet
Allemand
26/09/2024
Patient information leaflet
Français
26/09/2024
Patient information leaflet
Italien
26/09/2024
Professional SmPC
Allemand
26/09/2024
Professional SmPC
Français
26/09/2024
Professional SmPC
Italien
26/09/2024

Detailed composition

Substance Quantity Type Category
(N/A)
20.0 MG Substance Wirkstoff (Principe actif)
(N/A)
20.0 MG Substance Wirkstoff (Principe actif)
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance Konservierungsstoff (Conservateur)
(N/A)
0.007 UG Substance HBESI
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance Hilfsstoff ohne Deklarationspflicht (Excipient sans obligation de déclaration)
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance FTODK
(N/A)
- Substance FTODK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HBESI
(N/A)
- Substance Hilfsstoff ohne Deklarationspflicht (Excipient sans obligation de déclaration)
(N/A)
- Substance FIMDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
0.38 MG Substance HBESI

Reimbursement information

Public price
CHF 47.20
Specialties list
Yes
Generic
No
SL addition date: 01/04/2024

Authorization holder

Exeltis Suisse SA

1228 Plan-Ies-Ouates

Authorization information

Swissmedic authorization number
68867
Drug name
Bonjesta, Tablette mit veränderter Wirkstofffreisetzung
Galenic form
TABWF
ATC Code
R06AA59
Authorization status
Z
Dispensation category
B
First authorization
05/12/2023
Authorization expiration date
04/12/2028
IT number
01.09.0.
Domain
Human medicine
Field of application
symptomatischen Behandlung von Übelkeit und Erbrechen während der Schwangerschaft bei Frauen, die nicht auf eine konservative Behandlung ansprechen

Packaging details

Description (FR)
BONJESTA cpr ret 20mg/20mg 20 pce
Description (DE)
BONJESTA Ret Tabl 20mg/20mg 20 Stk
Market launch
05/12/2023
Narcotic (BTM)
No

Other packaging sizes